|
KMID : 0614620160670020064
|
|
Korean Journal of Gastroenterology
2016 Volume.67 No. 2 p.64 ~ p.73
|
|
|
Golimumab Therapy in Ulcerative Colitis
|
|
문원:Moon Won
저자없음:No authors listed
|
|
|
Abstract
|
|
|
|
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis.
|
|
|
KEYWORD
|
|
|
Ulcerative colitis, Tumor necrosis factor-alpha, Infliximab, Adalimumab, Golimumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|